shares are trading higher on Thursday, on continued strength after the company received FDA Breakthrough Device Designation for its cell-directed Selective Cytopheretic Device (SCD).

SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier ...

HAIFA, Israel , August 13 /PRNewswire/ -- SCD has announced the receipt of a phase I contract from DARPA, valued at $1.75 million, for the development of a new "XBn" infrared ...

Cardinal Health has launched the Kendall SCD SmartFlow device in the US, the latest in the company’s series of compression systems to mitigate the risk of venous thromboembolism events (VTE ...

The expanded infrastructure will enable production of IR solutions for high-end applications, including area dominance, ...

The SeaStar Medical presentation can be viewed on Friday, September 5, 2025, at 7:00 am Eastern Time. The presentation can be accessed by visiting the Events & Presentations page, located under the ...

In April 2025, SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its significant contribution to improving the lives of pediatric patients with AKI ...

“The SCD now has three Breakthrough Device Designations in total granted by the FDA’s Center for Biologics Evaluation and Research (CBER).

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...

SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier ...